title: Effects of serotonergic drugs on locomotor activity and vigilance states in ring doves.
abstract: Serotonergic system is implicated on sleep-waking states in mammals. Since studies on serotonin regulation of sleep in birds are scarce, ring dove was chosen as experimental subject in the present work. The role of the neurotransmitter serotonin on vigilance states was studied in ring doves intraperitoneally treated with the 5-HT(1A) agonist 8-OH-DPAT, the 5-HT(1A) antagonist WAY100635 and the inhibitor of serotonin synthesis para-chlorophenylalanine (PCPA) by means of behavioural, electrophysiological and infrared actimetry criteria. 8-OH-DPAT (1 mg/kg) treatment increased locomotor activity, active waking and grooming states and reduced SWS and REM sleep. Pre-treatment with WAY100635 (0.5 mg/kg) prevented the effects induced by 8-OH-DPAT. Serotonin depletion induced by PCPA treatment (two consecutive injections of 300 mg/kg over two consecutive days) reduced locomotor activity, waking and grooming activity while increased both SWS and REM sleep. Moreover, 8-OH-DPAT (0.5 mg/kg) in PCPA treated ring doves produced a notable rise in the locomotor activity, active waking and grooming states, while it decreased sleep. Altogether, the results support the idea that serotonin plays an active role in wakefulness, probably through the activation of 5-HT(1A) receptors that increases wake activities and reduces sleep in ring doves.
authors.affiliation: Laboratory of Neurophysiology, Department of Biologia Fonamental i Ciències de la Salut, University of the Balearic Islands, Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Palma de Mallorca, Spain. silvia.tejada@uib.es
authors.forename: S
authors.initials: S
authors.lastname: Tejada
authors.forename: R V
authors.initials: RV
authors.lastname: Rial
authors.forename: A
authors.initials: A
authors.lastname: Gamundí
authors.forename: S
authors.initials: S
authors.lastname: Esteban
mesh_terms: D017371:8-Hydroxy-2-(di-n-propylamino)tetralin / Q000494:pharmacology; D000818:Animals; D001143:Arousal / Q000187:drug effects*; D001288:Attention / Q000187:drug effects; D010856:Columbidae; D004569:Electroencephalography; D010134:Fenclonine / Q000494:pharmacology; D009043:Motor Activity / Q000187:drug effects*; D010879:Piperazines / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D012702:Serotonin Antagonists / Q000494:pharmacology*; D017366:Serotonin Receptor Agonists / Q000494:pharmacology*; D012890:Sleep / Q000187:drug effects*; D014851:Wakefulness / Q000187:drug effects*
chemical_list: D010879:Piperazines; D011725:Pyridines; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; C090413:N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide; D017371:8-Hydroxy-2-(di-n-propylamino)tetralin; D010134:Fenclonine